2-hydroxy-3-(octadecyloxy)propyl 2-(trimethylammonio)ethyl phosphate | 72490-82-5

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 甘油磷脂
• 英文名称: 2-hydroxy-3-(octadecyloxy)propyl 2-(trimethylammonio)ethyl phosphate
• 英文别名: Lyso-PAF c-18；(2-hydroxy-3-octadecoxypropyl) 2-(trimethylazaniumyl)ethyl phosphate
• CAS: 72490-82-5
• 化学式: C₂₆H₅₆NO₆P
• 分子量: 509.707
• InChiKey: XKBJVQHMEXMFDZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7
• 重原子数：
  34
• 可旋转键数：
  26
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  88
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  2-hydroxy-3-(octadecyloxy)propyl 2-(trimethylammonio)ethyl phosphate 以 吡啶 、 二氯甲烷 、 丙酮 为溶剂， 以69.4%的产率得到2-acetoacetyloxy-3-octadecyloxypropyl trimethylammonioethyl phosphate
  参考文献：
  名称：

  2-(acetoacetyloxy)-3-(octadecyloxy)propyl-3-trimethylammoniopropyl

  摘要：

  本发明提供的化合物具有以下结构式##STR1##其中R.sup.1为C.sub.14-20烷基；R.sup.2、R.sup.3和R.sup.4独立地为氢或C.sub.1-5烷基，或##STR2##代表环状铵基；A为C.sub.2-5烷基，以及其药用可接受盐，可用作抗肿瘤剂。

  公开号：

  US04710579A1
• 作为产物：
  描述：

  鲨肝醇 在 吡啶 、 palladium 10% on activated carbon 、 氢气 、 sodium hydride 、 对甲苯磺酸 、 三乙胺 作用下， 以 甲醇 、 二氯甲烷 、 N,N-二甲基甲酰胺 、 苯 为溶剂， 反应 42.5h， 生成 2-hydroxy-3-(octadecyloxy)propyl 2-(trimethylammonio)ethyl phosphate
  参考文献：
  名称：

  嵌合厄洛替尼-烷基磷脂杂种的设计，合成和细胞毒性。

  摘要：

  制备了两个系列的厄洛替尼-烷基磷脂杂种，并使用厄洛替尼和米替福辛作为参考标准，评估了它们对代表肺癌，乳腺癌，肝癌和皮肤癌的四种细胞系的抗增殖活性。酰胺类似物比类似酯引起的细胞毒性活性更高。酰胺衍生物8d和8e表现出有希望的广谱抗增殖活性，并且比参考厄洛替尼和米替福辛具有更高的疗效。对于8e和8d，它们的细胞GI50值分别在24.7-46.9μM和26.8-43.1μM的范围内。与统计相关分析相结合，制得的化合物对EGFR激酶反应和Akt磷酸化的抑制活性的测定结果表明，其他机制可能有助于其引起的细胞毒性。此外，统计相关分析表明，酰胺系列引发细胞毒性的机制可能与酯系列不同。另外，相关分析表明，根据细胞系类型的不同，机制也有所不同。

  DOI：

  10.1016/j.bioorg.2018.11.021

文献信息

• Synthesis and antitumor activity of new alkylphospholipids containing modifications of the phosphocholine moiety.
  作者：Kiyoshi UKAWA、Eiko IMAMIYA、Hiroaki YAMAMOTO、Katsutoshi MIZUNO、Akihiro TASAKA、Zen-ichi TERASHITA、Tetsuya OKUTANI、Hiroaki NOMURA、Takashi KASUKABE、Motoo HOZUMI、Ichiro KUDO、Keizo INOUE

  DOI：10.1248/cpb.37.1249

  日期：——

  New antitumor alkylglycerophospholipids, in which primarily the phosphocholine moiety of the platelet activating factor (PAF) molecule was modified, were synthesized from 1-alkyl-2-substituted glycerols by introducing polar head phosphoryl groups having methylene bridges of various lengths (from 2 to 14 carbons). They were tested for PAF agonistic activity and antitumor properties. In a series of 1-octadecyl-2-acetoacetylglycerophospholipids (1a-f), an increase in the length of the methylene bridge separating the phosphate and trimethylammonio group in the polar head side chain at position 3 of the glycerol backbone resulted in a progressive decrease in PAF agonistic activity and a characteristic change in antitumor activity against human promyelocytic leukemia cells (HL-60). Maximal potency was obtained with the compound having a decamethylene bridge (1e, IC50 value=1.5 μg/ml). Thus, alkylphospholipids possessing a decanmethylene bridge and a variety of substituents at position 2 (1g-n) were synthesized. They showed potent inhibitory activity with IC50 values ranging from 0.4 to 1.9 μg/ml, depending on the nature of the 2-substituent in the phospholipid molecule. In in vivo tests of the present series of alkylglycerophospholipids (1a-n), using mice bearing sarcoma 180 and mice with mammary carcinoma MM46 (both cells and compounds were given i.p.), 1-octadecyl-2-acetoacetyl-3-glyceryl ω-trimethylammoniodecyl phosphate (1e) showed the most potent life-prolonging effect. The structure-activity relationships are discussed.

  新型抗肿瘤烷基甘油磷脂是通过对血小板活化因子（PAF）分子中的磷酸胆碱部分进行修饰，从1-烷基-2-取代甘油中合成而得。通过引入具有不同长度（从2到14个碳）的亚甲基桥的极性头部磷酰基团进行了合成，并测试了其对PAF激动活性和抗肿瘤性质的影响。在一系列1-十八烷基-2-乙酰乙酰甘油磷脂（1a-f）中，随着甘油主链位置3处的磷酸和三甲铵基团之间的亚甲基桥长度增加，PAF激动活性逐渐降低，对人类早幼粒白血病细胞（HL-60）的抗肿瘤活性也发生了特征性变化。通过具有癸二烯桥的化合物（1e，IC50值=1.5μg/ml）获得了最大效力。因此，合成了具有癸二烯桥和在位置2具有各种取代基的烷基磷脂（1g-n）。它们表现出强烈的抑制活性，IC50值范围从0.4到1.9μg/ml，具体取决于磷脂分子中2-取代基的性质。在体内测试中，通过使用携带肉瘤180的小鼠和携带乳腺瘤MM46的小鼠（两种细胞和化合物均以腹腔途径给予），1-十八烷基-2-乙酰乙酰-3-甘油ω-三甲铵癸二烯磷酸酯（1e）表现出最强的延长寿命效果。讨论了结构-活性关系。
• Phospholipid derivatives, processes for preparation thereof and pharmaceutical composition of the same
  申请人：FUJISAWA PHARMACEUTICAL CO., LTD.

  公开号：EP0070433A1

  公开（公告）日：1983-01-26

  New phospholipid derivatives represented by the formula: wherein R' is alkyl, alkoxy, alkylthio, ar(lower)alkoxy or alkanoylamino; R2 is lower alkyl or ar(lower)-alkyl; n is an integer of 0 or 1; A is lower alkylene; R3 is pyridinio or a group of the formula: in which R5, R6 and R7 are each hydrogen or lower alkyl; and R4 is hydrogen or lower alkyl; and pharmaceutically acceptable salt thereof, which exhibit anti-hypertensive activity.

  由以下式子表示的新磷脂衍生物： 其中 R'是烷基、烷氧基、烷硫基、芳基（低级）烷氧基或烷酰氨基；R2是低级烷基或芳基（低级）-烷基；n是0或1的整数；A是低级亚烷基；R3是吡啶或式中的基团： 其中 R5、R6 和 R7 分别为氢 或低级烷基；以及 R4 是氢或低级烷基；及其药学上可接受的盐，具有抗高血压活性。
• Glycerol derivatives, their production and use
  申请人：Takeda Chemical Industries, Ltd.

  公开号：EP0094186A1

  公开（公告）日：1983-11-16

  Glycerol derivatives, inclusive of salts thereof, of the formula wherein R1 is alkyl or alkylcarbamoyl containing 10 to 30 carbon atoms, R2 and R3 are independently hydrogen, C1-6 alkyl or, taken toaether with the adiacent nitrogen atom form cyclic amino, and epresents cyclic ammonio, and of the formula wherein R1 is as defined above, R2' and R3' are C1-6 alkyl or, taken together with the adjacent nitrogen atom, form cyclic amino and R4' R5' and R6' are independently hydrogen or C1-6 alkyl, are useful as antihypertensive agents.

  甘油衍生物，包括其盐，其式为 其中 R1 是含有 10 至 30 个碳原子的烷基或烷基氨基甲酰基，R2 和 R3 独立地是氢、C1-6 烷基或与邻接的氮原子形成环氨基的醚，以及 代表环氨，其式如下 其中 R1 如上定义，R2'和 R3'为 C1-6 烷基或与邻近的氮原子形成环氨基，R4'、R5'和 R6'独立地为氢或 C1-6 烷基。
• Structure-activity relationship in PAF-acether. 3. Hydrophobic contribution to agonistic activity
  作者：Jean Jacques Godfroid、Colette Broquet、Simone Jouquey、Mariya Lebbar、Francoise Heymans、Catherine Redeuilh、Efroim Steiner、Elie Michel、Eliane Coeffier

  DOI：10.1021/jm00388a008

  日期：1987.5

  The synthesis of some selected PAF-acether homologues with an alkoxy-chain length from C1 to C20 in position 1 is described. All agonist activities are closely correlated among themselves and with the calculated fatty-chain hydrophobicity. After a discussion on recent published results and comparison with our data, we conclude that the ether oxide function is absolutely essential at the glycerol 1-position for potent agonist activity and that potency correlates well with hydrophobicity parameters. We indicate the importance of steric and configurational constraints.
• Synthesis of platelet activating factor (paf) via a cyclic tin intermediate
  作者：Michael M. Marx、Robert A. Wiley

  DOI：10.1016/s0040-4039(00)99049-x

  日期：1985.1